rabbit anti igfbp 5  (Proteintech)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology

doi: 10.1186/1756-9966-28-70

Figure Lengend Snippet: The relationship between expression of IGFBP-5 and cFLIP and clinicopathological parameters in CC

Article Snippet: Primary antibodies used in this study include IGFBP-5 rabbit anti-human polyclonal antibody (Boster Co., Ltd., Wuhan) and cFLIP rabbit anti-human polyclonal antibody (American Neomarker Co.).

Techniques: Expressing

Journal: Hepatology (Baltimore, Md.)

Article Title: Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.

doi: 10.1002/hep.22027

Figure Lengend Snippet: Fig. 5. Immunohistochemical detection of IGFBP-5 in hepatocellular carcinoma (HCC). HCC sections were stained with anti–IGFBP-5 antibody and counterstained with hematoxylin. Positive immunostaining appears brown. (A) Positive staining for IGFBP-5 in the cytoplasm of HCC cells, especially at the invasive boundaries. (B) Presence of IGFBP-5 in non- cancerous cirrhotic hepatocytes. (C) Stronger staining for IGFBP-5 in HCC cells (upper) than the neighboring cirrhotic hepatocytes (lower). (D) Positive staining for IGFBP-5 in HCC cells (upper left), but negative in cirrhotic cells (lower right). Bar, 100 m. (E) Correlation of expression levels of gankyrin and IGFBP-5 in HCCs. The immunostaining levels were expressed as 0 (negative), 1 (weakly positive), 2 (moderately pos- itive), or 3 (strongly positive). Each diamond represents 1 case. The Spearman’s rho 0.629, P 0.001. (F) Correlation of expression levels of gankyrin and IGFBP-5 in noncancerous hepatocytes determined as in (E). The Spearman’s rho 0.606, P 0.001.

Article Snippet: For immunohistochemistry, mouse monoclonal antigankyrin (3A6C2), anti-MDM2 (Ab-4, Oncogene research products, Boston, MA), and anti-p53 (DO-7, DAKO) antibodies, rabbit polyclonal anti-IGFBP-5 antibody (GroPep, Thebarton, Australia), and horseradish peroxidase–conjugated secondary antibodies against mouse or rabbit immunoglobulins (DAKO) were used.

Techniques: Immunohistochemical staining, Staining, Immunostaining, Expressing

Journal: Hepatology (Baltimore, Md.)

Article Title: Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.

doi: 10.1002/hep.22027

Figure Lengend Snippet: Fig. 4. Induction of IGFBP-5 by gankyrin. (A) U-2 OS cells (lanes 1 and 2) and Huh-7 cells (lanes 3 and 4) transiently transfected with plasmids expressing gankyrin or vector alone were analyzed for expres- sion of IGFBP-5 by western blotting using the indicated antibodies. Representative results from more than 3 experiments are shown. (B) Huh-7 cells, mock transfected or transfected with siRNA for gankyrin or control RNA as indicated, were analyzed as in (A). (C) Suppression of IGFBP-5 expression by siRNA. Huh-7 cells were transfected with control RNA or IGFBP-5–specific siRNA. IGFBP-5 transcript levels were deter- mined by real-time RT-PCR and normalized with -actin levels. Results from 3 repeats were averaged and expressed relative to control. Error bars refer to standard deviation of the average quantitated results. (D) Effect of IGFBP-5 down-regulation on cell growth. U-2 OS and Huh-7 cells were transfected with IGFBP-5 siRNA or control RNA, and 72 hours later viable cell numbers were determined. Values are mean standard deviation (n 3) and expressed relative to controls. ** and *, P 0.01 and P 0.05, respectively.

Article Snippet: For immunohistochemistry, mouse monoclonal antigankyrin (3A6C2), anti-MDM2 (Ab-4, Oncogene research products, Boston, MA), and anti-p53 (DO-7, DAKO) antibodies, rabbit polyclonal anti-IGFBP-5 antibody (GroPep, Thebarton, Australia), and horseradish peroxidase–conjugated secondary antibodies against mouse or rabbit immunoglobulins (DAKO) were used.

Techniques: Transfection, Expressing, Plasmid Preparation, Western Blot, Control, Quantitative RT-PCR, Standard Deviation

Journal: Hepatology (Baltimore, Md.)

Article Title: Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.

doi: 10.1002/hep.22027

Figure Lengend Snippet: Fig. 6. Survival of patients and expression of molecular markers. The Kaplan-Meier method was used to determine the patient survival and log-rank test to compare survival between patients with HCC grouped according to (A) gankyrin positivity, (B) p53 positivity, (C) MDM2 positivity, and (D) IGFBP-5 positivity. P, positive. N, negative.

Article Snippet: For immunohistochemistry, mouse monoclonal antigankyrin (3A6C2), anti-MDM2 (Ab-4, Oncogene research products, Boston, MA), and anti-p53 (DO-7, DAKO) antibodies, rabbit polyclonal anti-IGFBP-5 antibody (GroPep, Thebarton, Australia), and horseradish peroxidase–conjugated secondary antibodies against mouse or rabbit immunoglobulins (DAKO) were used.

Techniques: Expressing